PerkinElmer (PKI) says it's completed the acquisition of Shanghai Haoyuan Biotech, a China-based infectious disease diagnostics company, for $38M in cash plus future consideration based on the achievement of revenue-based targets. PKI says the deal should be immaterial to adjusted earnings for the remainder of 2012 and 2013 and accretive beginning in 2014.
PerkinElmer (PKI) says it's completed the acquisition of Shanghai Haoyuan Biotech, a China-based...
From other sites
at CNBC.com (May 5, 2014)
at CNBC.com (Apr 23, 2014)
at CNBC.com (Jan 29, 2014)
at CNBC.com (Dec 17, 2013)
at CNBC.com (Sep 16, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs